Monitoring the hepatitis C epidemic in England and evaluating intervention scale‐up using routinely collected data.

Summary: In England, 160 000 individuals were estimated to be chronically infected with hepatitis C virus (HCV) in 2005 and the burden of severe HCV‐related liver disease has increased steadily for the past 15 years. Direct‐acting antiviral treatments can clear infection in most patients, motivating HCV elimination targets. However, the current burden of HCV is unknown and new methods are required to monitor progress. We employed a Bayesian back‐calculation approach, combining data on severe HCV‐related liver disease and disease progression, to reconstruct historical HCV incidence and estimate current prevalence in England. We explicitly modelled infections occurring in people who inject drugs, the key risk group, allowing information on the size of this population and surveillance data on HCV prevalence to inform recent incidence. We estimated that there were 143 000 chronic infections in 2015 (95% credible interval 123 000‐161 000), with 34% and 54% in those with recent and past injecting drug use, respectively. Following the planned scale‐up of new treatments, chronic infections were predicted to fall to 113 400 (94 900‐132 400) by the end of 2018 and to 89 500 (71 300‐108 600) by the end of 2020. Numbers developing severe HCV‐related liver disease were predicted to fall by at least 24% from 2015 to 2020. Thus, we describe a coherent framework to monitor progress using routinely collected data, which can be extended to incorporate additional data sources. Planned treatment scale‐up is likely to achieve 2020 WHO targets for HCV morbidity, but substantial efforts will be required to ensure that HCV testing and patient engagement are sufficiently high. People who inject drugs are at high risk of acquiring hepatitis C infection, many of whom will develop cirrhosis and severe liver disease. We use surveillance data to model this process, estimating the number of HCV‐infected people in England and predicted impact of new treatments. We estimate 143,000 people had chronic infection in 2015 and predict that this will fall to around 90,000 in 2020. [ABSTRACT FROM AUTHOR]